首页> 外文期刊>International journal of hyperthermia: The official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group >Relationships between thermal dose parameters and the efficacy of definitive chemoradiotherapy plus regional hyperthermia in the treatment of locally advanced cervical cancer: data from a multicentre randomised clinical trial
【24h】

Relationships between thermal dose parameters and the efficacy of definitive chemoradiotherapy plus regional hyperthermia in the treatment of locally advanced cervical cancer: data from a multicentre randomised clinical trial

机译:热剂量参数与确定性放化疗联合局部热疗在局部晚期宫颈癌治疗中的关系:来自多中心随机临床试验的数据

获取原文
           

摘要

Purpose: To evaluate the contribution of the thermal dose parameters during regional hyperthermia (HT) treatment to the clinical outcomes in patients with cervical carcinoma (CC) who received chemoradiotherapy (CRT) plus HT. Materials and methods: Data from a multicentre randomised clinical trial of concurrent CRT?+?HT vs. CRT alone were used to evaluate the efficacy and safety of this combination therapy in the CC patients. The intrarectal temperatures of patients undergoing HT were recorded. The complete thermal data of 47 (92%) of the 51 patients in the CRT?+?HT group were available for the thermal analysis. Thus, 47 patients who received CRT?+?HT were included in the present study. Results: Among the patients who received CRT?+?HT, a higher CEM43T90 (≥1?min) value (a thermal dose parameter) was significantly associated with better local relapse-free survival in both univariate (p?=?0.024) and multivariate (p?=?0.0097) analyses. The disease-free survival of the patients with higher CEM43T90 (≥1?min) values tended to be better in comparison to patients with lower CEM43T90 (p?=?0.071). A complete response tended to be associated with the CEM43T90 (p?=?0.056). Disease-free survival, local relapse-free survival and complete response rate for patients with higher CEM43T90 (≥1) were significantly better than those for patients with CRT alone (p?=?0.036, p?=?0.036 and p?=?0.048). Conclusions: Dose-effect relationships between thermal dose parameters and clinical outcomes were confirmed in the CC patients treated with a combination of CRT?+?HT. This study also confirmed that HT with lower CEM43T90 is insufficient to achieve a significant hyperthermic sensitisation to CRT.
机译:目的:评估局部热疗(HT)治疗期间热剂量参数对接受化学放射疗法(CRT)加HT治疗的宫颈癌(CC)患者临床结局的影响。材料和方法:同时进行CRT + HT与单独CRT的多中心随机临床试验数据用于评估该联合治疗对CC患者的疗效和安全性。记录接受HT的患者的直肠内温度。 CRT?+?HT组的51例患者中有47例(92%)的完整热数据可用于热分析。因此,本研究纳入了47位接受CRT?+?HT治疗的患者。结果:在接受CRT + HT的患者中,单变量(p = 0.024)和较高的CEM43T90(≥1 µmin)值(热剂量参数)与更好的局部无复发生存率显着相关。多元(p?=?0.0097)分析。 CEM43T90值较高(≥1?min)的患者的无病生存率往往比CEM43T90值较低的患者(p?=?0.071)更好。完全响应倾向于与CEM43T90相关(p = 0.056)。 CEM43T90(≥1)较高的患者的无病生存期,局部无复发生存率和完全缓解率显着优于单纯CRT患者(p <= 0.036,p == 0.036和p ==? 0.048)。结论:在接受CRT?+?HT联合治疗的CC患者中,证实了热剂量参数与临床结局之间的剂量效应关系。这项研究还证实,具有较低CEM43T90的HT不足以实现对CRT的显着热敏化。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号